Prof. Chandi C. Mandal

Brief overview:

Prof. Chandi C. Mandal's research  aims at understanding molecular mechanisms of dysregulated gene expressions and cellular signalling networks associated with debilitating cancer diseases, by carrying out cell-based experiments, clinical cancer tissues, animal study and database analysis. Exploring the impact of various metabolic disorders (e.g., diabetes, obesity and hypercholesterolemia) and extrinsic risk factor (e.g., cold exposure) influence on the peculiar trans-differentiation property of epithelial breast cancer cells into osteoblast and adipocyte-like cells is a major focus. Committed to translational relevance, we prioritize non-toxic therapeutic candidates capable of disrupting oncogenic signalling by directly modulating gene targets. The team also examines whether cholesterol-lowering statins, omega-3 fatty acids, and the anti-diabetic drug metformin can be combined with other anti-cancer agents to improve therapeutic efficacy.

Dr. Mandal's academic endeavour is not only reflected in the publications of his research work, but he is also recipient of Investigator Award from ASBMR, USA and Fellowship Award from CPRIT, USA.  His research work has also been highlighted multiple times in Newspaper and reported in Television channels. He is a member of several professional societies such as IACR, BRSI, ISCA, and Fellow of Royal Society of Biology (FRSB) UK.

He is editorial board member of various reputed journals such as associate editor of “Frontiers in Endocrinology-bone section” and “BMC Cancer”, and academic editor of “PLOS ONE”, and editorial member of "Scientific Reports [npg]" , "Journal of Biochemical and Molecular Toxicology”, "Oncology Letters" and “Indian Journal of Medical Research (ICMR)". He has been enlisted in the TOP 2% scientists in 2021, 2023-2025, published in Plos Biology.